Noble Financial Comments on GeoVax Labs Q1 Earnings

GeoVax Labs Inc. (NASDAQ:GOVX) – Investment analysts at Noble Financial issued their Q1 2027 earnings per share estimates for GeoVax Labs in a research note issued on Wednesday, July 29th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings per share of ($0.63) for the quarter. The consensus estimate for GeoVax Labs’ current full-year earnings is ($8.69) per share. Noble Financial also issued estimates for GeoVax Labs’ Q2 2027 earnings at ($0.66) EPS, Q3 2027 earnings at ($0.67) EPS and Q4 2027 earnings at ($0.68) EPS.

Other analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Friday, July 17th. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. Finally, D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research report on Thursday, April 16th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $150.00.

GeoVax Labs Price Performance

GOVX opened at $0.70 on Thursday. The firm has a fifty day moving average price of $1.47 and a 200 day moving average price of $1.77. GeoVax Labs has a 1 year low of $0.64 and a 1 year high of $20.62. The stock has a market cap of $2.42 million, a P/E ratio of -0.04 and a beta of 3.68.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings data on Monday, July 27th. The company reported ($0.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.16) by $1.19.

Hedge Funds Weigh In On GeoVax Labs

A number of large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new position in GeoVax Labs during the first quarter valued at $27,000. Armistice Capital LLC purchased a new stake in shares of GeoVax Labs during the third quarter worth about $253,000. Renaissance Technologies LLC purchased a new stake in shares of GeoVax Labs during the fourth quarter worth about $104,000. Finally, HRT Financial LP acquired a new position in shares of GeoVax Labs during the 4th quarter worth about $31,000. 6.09% of the stock is currently owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.